Clinical pharmacology and therapeutics, 2017-07, Vol.102 (1), p.45-51
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
- Ist Teil von
- Clinical pharmacology and therapeutics, 2017-07, Vol.102 (1), p.45-51
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2017
- Quelle
- Wiley Online Library Journals Frontfile Complete
- Beschreibungen/Notizen
- Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0009-9236eISSN: 1532-6535DOI: 10.1002/cpt.583Titel-ID: cdi_crossref_primary_10_1002_cpt_583
- Format
- –
- Schlagworte
- Antifungal Agents - pharmacokinetics, Antifungal Agents - therapeutic use, Cytochrome P-450 CYP2C19 - genetics, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions - metabolism, Drug-Related Side Effects and Adverse Reactions - prevention & control, Genotyping Techniques - methods, Humans, Metabolic Clearance Rate - physiology, Patient Selection, Pharmacogenomic Variants - genetics, Risk Assessment - methods, Voriconazole - pharmacokinetics, Voriconazole - therapeutic use